



Universiteit  
Leiden  
The Netherlands

## **The role of the ubiquitin system in human cytomegalovirus-mediated degradation of MHC class I heavy chains**

Hassink, G.C.

### **Citation**

Hassink, G. C. (2006, May 22). *The role of the ubiquitin system in human cytomegalovirus-mediated degradation of MHC class I heavy chains*. Retrieved from <https://hdl.handle.net/1887/4414>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4414>

**Note:** To cite this publication please use the final published version (if applicable).

**CHAPTER 7 HUMAN CYTOMEGALOVIRUS-  
ENCODED US2 AND US11 TARGET  
UNASSEMBLED MHC CLASS I HEAVY  
CHAINS FOR DEGRADATION**

Martine Barel, Gerco Hassink, Sjaak van Voorden and  
Emmanuel Wiertz

*Molecular Immunology* 43 (2006) pp1258-66



## Abstract

Surface MHC class I molecules serve important immune functions as ligands for both T and NK cell receptors for the elimination of infected and malignant cells. In order to reach the cell surface, MHC class I molecules have to fold properly and form trimers consisting of a heavy chain (HC), a  $\beta$ 2-microglobulin light chain and an 8–10-mer peptide. A panel of ER chaperones facilitates the folding and assembly process. Incorrectly assembled or folded MHC class I HCs are detected by the ER quality-control system and transported to the cytosol for degradation by proteasomes. In human cytomegalovirus-infected cells, two viral proteins are synthesized, US2 and US11, which target MHC class I HCs for proteasomal degradation. It is unknown at which stage of MHC class I folding and complex formation US2 and US11 come into play. In addition, it is unclear if the disposal takes place via the same pathway through which proteins are removed that fail to pass ER quality control. In this study, we show with a  $\beta$ 2m-deficient cell line that US2 and US11 both target unassembled HCs for degradation. This suggests that US2 and US11 both act at an early stage of MHC class I complex formation. In addition, our data indicate that US11-mediated degradation involves mechanisms that are similar to those normally used to remove terminally misfolded HCs.

## Introduction

MHC class I molecules are important reporters for the immune system. They display small peptide fragments derived from the total cellular protein pool at the cell surface for inspection by cytotoxic T cells <sup>1</sup>. In case of a virus infection, they will carry peptides derived from viral proteins and thus signal the presence of the viral invader to the immune system. In addition, the absence or presence of MHC class I molecules can be sensed by NK cells and regulate their activation <sup>2</sup>.

In order to reach the cell surface, MHC class I molecules have to fold properly and form a trimeric complex that consists of a heavy chain (HC; 43 kDa),  $\beta$ 2-microglobulin ( $\beta$ 2m; 12 kDa) and an 8–10-mer peptide. The folding and assembly process occurs in an orderly fashion and is facilitated by several ER chaperones.

MHC class I HCs encode a signal peptide, which directs insertion into the ER during translation. Once in the ER, the signal sequence is cleaved off by a signal peptidase. An oligosaccharyl transferase equips the HC with an N-linked oligosaccharide at residue N86. At this stage, free HCs are found in

association with the general ER chaperones immunoglobulin binding protein (BiP) <sup>3</sup> and calnexin (CNX), the latter of which is a membrane bound protein with lectin-like activity <sup>4,5</sup>. BiP binds transiently to many newly synthesized proteins and for prolonged times to misfolded proteins or unassembled subunits <sup>6</sup>. Binding of CNX is regulated by glucose trimming of nascent N-linked oligosaccharides <sup>7</sup>. CNX generally binds proteins with monoglucosylated (Glc1Man9–7GlnNAc2) oligosaccharides <sup>8</sup>. CNX and BiP predominantly associate with free MHC class I HCs and the assembly with  $\beta$ 2m abolishes the interaction of the HC with these chaperones <sup>3,9,10</sup>. Before binding the light chain, HCs also interact with ERp57, a member of the protein disulfide isomerase family, involved in disulfide bond oxidation, reduction and isomerization reactions <sup>11</sup> Ellgaard and Helenius, 2001 <sup>12</sup>. Mature MHC class I molecules harbor three intra-molecular disulfide bridges, the formation of which is likely to be mainly assisted by ERp57.

After binding  $\beta$ 2m, MHC class I molecules are found in association with another, soluble ER chaperone with lectin-like activity, calreticulin (CRT) <sup>13,14</sup>. Like CNX, CRT binds to proteins with Glc1Man9–7GlnNAc2 N-linked oligosaccharides <sup>15,16</sup>. Next, the MHC class I molecules associate with the peptide-loading complex, which besides CRT includes ERp57, tapasin and the transporter associated with antigen processing (TAP). Tapasin mediates the interaction of HCs with the TAP complex <sup>13,14,16</sup>. Peptides generated from endogenous proteins by proteasomal degradation are transported from the cytosol into the ER via the TAP complex, where they can be trimmed further by amino-peptidases before loading onto HC– $\beta$ 2m dimers <sup>17,18</sup>. Trimeric HC– $\beta$ 2m–peptide complexes dissociate from the loading complex and are released into the secretory pathway <sup>19</sup>. In contrast, incompletely assembled MHC class I HCs are recognized by the ER quality-control system and are targeted for degradation <sup>20</sup>.

In the course of HCMV infection, several viral proteins are synthesized which prevent MHC class I surface expression. These immune evasion proteins obstruct different steps of the folding and assembly pathway of MHC class I molecules. The unique short region 3 (US3) gene product retains MHC class I molecules in the ER and specifically affects those MHC class I molecules whose surface expression is tapasin-dependent <sup>21</sup>. US6 blocks peptide transport by TAP, thereby preventing the formation of stable trimeric MHC class I complexes <sup>22,23</sup>. Two other HCMV gene products, US2 and US11, target MHC class I HCs for proteasomal degradation in the cytosol <sup>24-26</sup>.

It is unknown if US2 and US11 make use of the regular ER quality-control pathway for disposal of class I molecules. It is also unclear to what extent MHC class I molecules have to be folded and complexed with  $\beta$ 2m

and/or peptide before US2 and US11 can bind to these proteins. These aspects of US2- and US11-mediated HC degradation are investigated in the present study using a  $\beta$ 2m-deficient cell line.


## Results

It is unclear at what stage of folding and assembly of newly synthesized MHC class I HCs US2 and US11 come into play to redirect these molecules back to the cytosol for subsequent proteasomal degradation. We evaluated if US2 and US11 can target heavy chains for degradation at an early stage, namely when they are still unassembled. A  $\beta$ 2m-negative cell line was used to address this question.

A report by Furman et al. indicated that the redox status influences degradation of class I heavy chains by US2 and US11<sup>27</sup>. Mature and fully assembled MHC class I complexes contain three disulfide bonds: one within the  $\beta$ 2m light chain and two within the heavy chain. The disulfide bonds in the heavy chain are located in the membrane-proximal  $\alpha$ 3 domain and in the  $\alpha$ 2 domain, the latter of which forms part of the peptide binding groove. Pulse chase experiments with wild-type and mutant (C203S + C259S) HLA-A2 revealed that formation of a disulfide bond in the  $\alpha$ 3 domain of class I was essential for US2-mediated degradation, but not for degradation mediated by US11<sup>27</sup>. Besides this, several studies indicated that the presence of  $\beta$ 2m supports disulfide bond formation in MHC class I HCs<sup>28,29</sup>. In the absence of  $\beta$ 2m class I HCs cycle between (fully) oxidized and reduced states<sup>30</sup>. In our current study, we make use of the  $\beta$ 2m-negative FO-I cell line. Before looking at the effect of US2 and US11 expression on degradation of class I heavy chains, we first investigated the differences in oxidation status of class I HCs in this cell line.

### **Shortly after synthesis, the majority of free class I HCs is fully oxidised in the absence or presence of $\beta$ 2m**

We evaluated the oxidation status of MHC class I heavy chains in  $\beta$ 2m-negative (FO-I wild-type) and  $\beta$ 2m-reconstituted (FO-I +  $\beta$ 2m) cell lines over time in pulse chase experiments (Fig. 1). MHC class I heavy chains were recovered from NP40 lysates (supplemented with the alkylating agent NEM to prevent post-lysis formation of disulfide bonds), using either HC10 or W6/32 monoclonal antibodies. Samples were separated by SDS-PAGE under non-reducing conditions. Under these circumstances, three distinct bands can be observed of which the intensity and migration patterns change at increasing concentrations of the reducing agent DTT (Fig. 1A). The fastest, middle and slowest migrating bands reflect fully oxidized (two disulfide




**Figure 1. Shortly after synthesis, the majority of free class I HCs are fully oxidised in the presence or absence of  $\beta$ 2m.**

(A) FO-I cells, which have a defective  $\beta$ 2m gene and FO-I cells restored for  $\beta$ 2m expression were metabolically labeled with  $^{35}\text{S}$  Met/Cys for 60 min. Cells were lysed in NP40 lysis mix (supplemented with NEM) and MHC class I HCs were recovered using MoAbs HC10 (recognizing free class I HCs) or W6/32 (recognizing properly folded,  $\beta$ 2m-associated MHC class I complexes). After immunoprecipitation, samples were split and taken up in sample buffer without or with DTT at the concentrations indicated. Samples were separated by SDS-PAGE (12.5% gel). (B) Cells were labeled for 5 min and chased for the times indicated. After immunoprecipitation, samples were split and treated with PNGaseF or mock-treated. Samples were taken up in non-reducing sample buffer. The migration pattern of class I HCs with 0, 1 or 2 disulfide bonds is indicated with arrows.

bonds), partially reduced (one disulfide bond) and completely reduced HCs (no disulfide bonds), respectively.

HC10 is specific for free HCs and recognizes all HCs expressed in the  $\beta$ 2m-negative cells (Fig. 1B, lanes 1–4). In the  $\beta$ 2m-reconstituted cells, HC10 interacts with only a fraction of the HC pool, likely those still unassembled (lanes 5–8). W6/32 only recognizes HCs associated with  $\beta$ 2m (lanes 13–16) and does not recognize HCs expressed in cells lacking  $\beta$ 2m (Fig. 1B, upper panel, lanes 9–12). To exclude a contribution of maturation of the N-linked sugar chain on the migration pattern of HCs, part of the samples was treated with PNGase F (Fig. 1B, lower panel). In the presence of  $\beta$ 2m, all W6/32-reactive material was fully oxidized (lanes 13–16), like the majority of the HC10-reactive material (lanes 5–8). In contrast, a small amount of fully and partially reduced HC10-reactive HCs was observed in the  $\beta$ 2m-negative cells (lanes 1–4). The relative proportion of reduced, partially reduced and oxidized HCs varied in the course of the chase in the  $\beta$ 2m-negative cells. Right after the pulse and up to 30 min into the chase, the majority of HCs were fully oxidized (lanes 1–3, lower band). After 60 min chase, the total amount of



**Figure 2. Unassembled HCs are targeted for degradation by US2 and US11.**

FO-I cells restored for  $\beta 2m$  expression (+ $\beta 2m$ , panel A) and wild-type FO-I cells <sup>51</sup> panel B) were transduced with wt-EGFP, US2-EGFP or US11-EGFP-encoding retrovirus and sorted for EGFP expression. Cells were metabolically labeled with <sup>35</sup>S Met/Cys for 10 min and chased for the times indicated. MHC class I HCs, transferrin receptor (TfR), US2 and US11 were recovered from denatured samples, taken up in reducing sample buffer, separated by SDS-PAGE (12.5% gel) and visualized using a phosphor-imager. The amount of precipitated MHC class I HCs, normalized on the basis of TfR levels, is displayed as the percentage of HC levels found at the onset of chase in wt-EGFP cell lines. The results are based on multiple observations; a representative experiment is shown

MHC class I was decreased. This is consistent with previous data showing degradation of free HCs in the absence of  $\beta 2m$  <sup>20</sup>. After 60 min of chase, especially, a reduction in the amount of fully oxidized HCs was observed and a small increase in the more reduced forms, relative to the total amount of HCs (lane 4).

Since US2 and US11 are known to act within a relatively short time window (within minutes after MHC class I synthesis), they are likely to encounter fully oxidized free HCs in both  $\beta 2m$ -positive and -negative cells.

### **Unassembled HCs are targeted for degradation by US2 and US11**


Next, we introduced US2 and US11 into the FO-I cell lines to evaluate if these viral proteins can target MHC class I heavy chains for degradation in the absence of  $\beta 2m$  (Fig. 2). After cell lysis, samples were denatured to ensure that HC10 was able to immunoprecipitate all HCs present in FO-I cell lysates. Samples were separated by SDS-PAGE under reducing conditions. The transferrin receptor was immunoprecipitated as an internal control for cell labeling and sample loading. In FO-I cells reconstituted for  $\beta 2m$  expression (Fig. 2A), MHC class I heavy chains remained stable over time in the absence of viral proteins (lanes 1–3, 7–9), but were destabilized in the presence of US2 (lanes 4–6) or US11 (lanes 10–12). Note that most of the HCs have already been degraded during the 10 min pulse, while the transferrin receptor remained stable (lanes 4 and 10). Fig. 2B shows the effect of US2 and US11 on the stability of HCs in the absence of  $\beta 2m$ . In the presence of US2 (lanes 16–18), less HCs could be immunoprecipitated compared to the amount recovered from US2-negative cells, while transferrin receptor levels remained the same in both cell lines (lanes 13–15). Similar results were obtained in US11-expressing FO-I cells (compare lanes 22–24 with 19–21).

Thus, US2 and US11 can target unassembled HCs for degradation, indicating that they can act already at an early stage of MHC class I folding and complex formation.

### **US11 can target HCs to the cytosol in the absence of $\beta 2m$ , but this action is severely compromised when proteasomal activity is blocked**

Dislocated MHC class I heavy chains can be visualized using proteasome inhibitors. The N-linked glycans are removed from retro-translocated HCs by a cytosolic N-glycanase, before the HCs are degraded by proteasomes. Thus, in the presence of proteasome inhibitors, deglycosylated breakdown intermediates become visible that are characterized by a faster migration in SDS-PAGE<sup>31 25,26</sup>.

To complement the data shown in Fig. 2, experiments were performed in the presence of proteasome inhibitor ZL3H (Fig. 3). Fig. 3A shows that in  $\beta 2m$  expressing cells, HCs remain stable in the absence of viral proteins (lanes 1–3). In US2+ (lanes 4–6) and US11+ cells (lanes 7–9), a decrease is observed in the amount of glycosylated HCs (HC + CHO) and an increase in the amount of deglycosylated breakdown intermediates (HC–CHO). The results have been quantified and displayed graphically, with HC + CHO in dark gray and HC–CHO in light gray. Fig. 3B shows the results for the  $\beta 2m$ -negative cells. A similar conversion from glycosylated HCs to deglycosylated breakdown intermediates could be observed for the US2+ cells (lanes 13–15), comparable to what was observed for the  $\beta 2m$ +, US2+ cells (lanes 4–6). In




**Figure 3. US11 can target HCs to the cytosol in the absence of  $\beta$ 2m, but this action is severely compromised when proteasomal activity is blocked.**

FO-I cells restored for  $\beta$ 2m expression<sup>51</sup> panel A) and wild-type FO-I cells<sup>51</sup> panel B) were transduced with wt-EGFP, US2-EGFP or US11-EGFP-encoding retrovirus and sorted for EGFP expression. Cells were metabolically labeled with <sup>35</sup>S Met/Cys for 10 min and chased for the times indicated, all in the presence of proteasome inhibitor. MHC class I HCs, US2 and US11 were recovered from denatured lysates by immunoprecipitation. Samples were taken up in reducing loading buffer, separated by SDS-PAGE (12.5% gel) and visualized using a phosphor-imager. Arrows indicate the migration pattern of proteins +/- N-linked glycan (CHO). The amount of MHC class I HCs +CHO or -CHO is given as a percentage of the total pool of MHC class I HCs (+ and -CHO) precipitated from that sample. Results are based on multiple observations; a representative experiment is shown.

contrast, only a minor fraction of HC breakdown intermediates could be observed in the US11+,  $\beta$ 2m- cells (lanes 16–18) as compared to the US11+,  $\beta$ 2m+ cells (lanes 7–9) and the US2+,  $\beta$ 2m- cells (lanes 13–15).

These data again show that US2 can target unassembled HCs for degradation and suggest that it can do so equally well in the presence or absence of  $\beta$ 2m, with or without proteasome inhibitor. In contrast, proteasome inhibition appears to interfere with the action of US11 in cells



**Figure 4. Inhibition of proteasome activity delays dislocation of unassembled HCs in  $\beta$ 2m-negative cells in the absence of viral proteins.**

Wild-type FO-I cells were metabolically labeled with  $^{35}\text{S}$  Met/Cys for 10 min and chased in the presence or absence of proteasome inhibitor (+/-ZL3H) for the times indicated. MHC class I HCs were recovered from denatured samples, taken up in reducing sample buffer, separated by SDS-PAGE (12.5% gel) and visualized using a phosphor-imager. Arrows indicate migration pattern of HCs +/- N-linked glycan (CHO). The amount of MHC class I HCs +CHO precipitated at different time points (relative to the total amount of HCs at the onset of the chase) is displayed graphically.

lacking  $\beta$ 2m.

#### **Inhibition of proteasome activity also delays dislocation of unassembled HCs in $\beta$ 2m-negative cells in the absence of viral proteins**

In the absence of  $\beta$ 2m, MHC class I HCs become a target for ER quality-control mechanisms that ensure disposal of improperly assembled HCs. This has been shown using the  $\beta$ 2m-negative Daudi cell line <sup>20</sup>. Pulse chase experiments showed that the dislocation and degradation of MHC class I heavy chains takes place at a slower pace, with the first signs of dislocation at 30 min after a 10 min labeling time. We investigated if the dislocation of unassembled HCs requires proteasomal activity. For this purpose, equal amounts of wild-type FO-I cells were pulse-labeled and chased up to 120 min either in the absence or presence of proteasome inhibitor (Fig. 4). Equal amounts of glycosylated HCs could be precipitated at the start. Over the course of the chase, some decrease in the amount of glycosylated HCs was observed in cells treated with proteasome inhibitor. This was accompanied by a slight increase in the amount of deglycosylated HCs. However, the decrease of glycosylated HCs was more pronounced in the absence of proteasome inhibitor.

These results indicate that the quality-control-associated dislocation of unassembled HCs is less efficient when proteasomal activity is blocked.

## **Discussion**

HCMV encodes several immune evasion proteins that prevent MHC class I surface expression. These viral gene products can obstruct different

steps of the folding and assembly pathway of MHC class I molecules. We investigated at what stage of the assembly process MHC class I HCs are redirected to the cytosol by US2 and US11 for proteasomal degradation.

Previous observations suggest that US2 prefers properly folded and assembled HCs as target; it can be found in association with assembled MHC class I molecules (indicated by its co-precipitation with the conformation-dependent anti-MHC I complex antibody W6/32)<sup>26</sup>. In addition, US2 co-crystallized with class I HC- $\beta$ 2m-peptide complexes<sup>32</sup>.

In this study, we evaluated if US2 and US11 are capable of targeting free HCs for degradation. For this purpose, we used a human melanoma cell line (FO-I), which does not express  $\beta$ 2m<sup>33</sup>.  $\beta$ 2m-reconstituted FO-I cells served as a control. Surprisingly, US2 as well as US11 could target free HCs for degradation. Moreover, this occurred with an efficiency that appeared to be similar to that observed in cells expressing  $\beta$ 2m (Fig. 2). This shows that US2 and US11 can both act at early stages of MHC class I assembly.

These data are in disagreement with a previous report, which suggested that US2-mediated dislocation of MHC class I HCs requires assembly with  $\beta$ 2m<sup>31</sup>. This conclusion was based on experiments performed with a human astrocytoma cell line, U373-GM, in which RNA interference (RNAi) was used to knock-down  $\beta$ 2m expression. US2-mediated dislocation of class I HCs was much less efficient in these  $\beta$ 2m-knock-out cells than in wild-type cells, as indicated by a slower conversion of glycosylated to deglycosylated HCs in the presence of proteasome inhibitor. Our data suggest that another factor than the absence of  $\beta$ 2m may be responsible for the reduced US2-mediated retrograde transport of HCs in the U373-GM  $\beta$ 2m-knock-down cells. In our experiments, we could see similar amounts of deglycosylated breakdown intermediates for both FO-I and  $\beta$ 2m-reconstituted FO-I cells (expressing similar amounts of US2), when proteasome inhibitor was included (Fig. 3). It may be that cell type-specific factors render FO-I cells more suitable to facilitate US2-mediated degradation of free HCs than U373-MG cells. Alternatively, the RNAi construct used may, besides knocking-down  $\beta$ 2m expression, also influence the expression of other factors important for the efficiency of the dislocation process.

We showed that HCs do not require assembly with  $\beta$ 2m in order to become targets for US11 either. The efficiency of HC degradation in the presence of US11 is similar in  $\beta$ 2m+ and  $\beta$ 2m- FO-I cells (Fig. 2). Interestingly, the inclusion of proteasome inhibitor seriously obstructed the dislocation efficiency of HCs, but only in US11+,  $\beta$ 2m- cells (Fig. 3). This was not observed in US2+  $\beta$ 2m+, US2+,  $\beta$ 2m- nor US11+  $\beta$ 2m+ cells. Why was this obstruction of dislocation only seen in the presence of proteasome inhibitor and why only in cells lacking  $\beta$ 2m expression? And, why is this

observed in US11-positive cells, but not in cells expressing US2?

In the absence of US2 or US11, incompletely folded or assembled MHC class I molecules are also removed from the ER and transported to the cytosol where they are degraded by proteasomes<sup>20</sup>. We showed that the dislocation of unassembled HCs in FO-I cells occurred with lower efficiency in the presence of proteasome inhibitors, in the absence of US11 (Fig. 4). A similar observation has been reported for  $\beta$ 2m-negative Daudi cells<sup>34</sup>. Interestingly, treatment with chemicals that interfere with disulfide bond formation (diamide, NEM), also abrogated dislocation of HCs in Daudi cells<sup>34</sup>.

MHC class I HCs expressed in cell lines with or without  $\beta$ 2m are known to differ for their interaction with ER chaperones. Analysis of human  $\beta$ 2m-deficient cells has shown that the light chain is required for correct folding, calreticulin and TAP binding, peptide loading, intracellular transport and cell surface expression of HLA class I heavy chains<sup>14,35</sup>. In the absence of  $\beta$ 2m, HCs do not enter the secretory pathway, but remain associated for a prolonged time with BiP and calnexin<sup>36,10</sup>. The exact mechanism by which misfolded and unassembled molecules are finally removed from the ER remains elusive, but there are indications that these ER chaperones may play a role in this process.

BiP is known to retain many misfolded proteins in the ER<sup>37</sup>, including unassembled MHC class I HCs<sup>3</sup>. Studies with mutant Kar2p (the yeast homologue of BiP) and mutant glycoprotein (CPY\*), have shown a correlation between the ATPase activity of Kar2p and release of malformed proteins into the cytosol<sup>38</sup>. In another report, the release from BiP of the unassembled Ig light chain and its retro-translocation out of the ER was studied<sup>39</sup>. The dislocation of this soluble, non-glycosylated protein seemed to be tightly coupled to proteasome activity.

Calnexin, a lectin chaperone, assists the folding of many glycoproteins<sup>7,40</sup>. It can also contribute to oxidative folding, as it acts in conjunction with the oxidoreductase ERp57<sup>41</sup>. We showed that in the absence of  $\beta$ 2m, the majority of HCs is fully oxidized shortly after synthesis. When these HCs are followed in time, a larger amount, relative to the total HC pool at that time, is found in a partially or completely reduced state (Fig. 1). The total amount of HCs gradually becomes less, as unassembled HCs are targeted for degradation<sup>(20; Fig. 4)</sup>. This conversion of HCs to a reduced state may be a prerequisite for efficient dislocation. The finding that diamide and NEM abrogated dislocation in the  $\beta$ 2m-negative Daudi cell line supports the idea that the protein redox status influences the dislocation process<sup>34</sup>. There are indications that proteasome inhibitors may interfere with CNX/oxidoreductase interactions<sup>42,43</sup>. In cells treated with lactacystin, a

redistribution of ER chaperones was observed: upon proteasome inhibition, CNX, CRT and ER degradation substrates (but not BiP, PDI, glucosyltransferase, ERp57) accumulated in a pericentriolar quality-control compartment derived from the ER <sup>42,43</sup>.

The fact that we found an abrogation of US11-mediated dislocation, in the presence of proteasome inhibitor only and exclusively in cells lacking  $\beta$ 2m expression may imply that US11 uses partially similar mechanisms for discarding HCs as the constitutive pathway used by FO-I cells to dispose of unassembled class I molecules in the absence of any viral proteins.

All in all, we conclude that US2 and US11 can act on MHC class I molecules at an early stage of folding and assembly. In addition, our data indicate a link between the endogenous pathway for disposal of terminally misfolded proteins and US11-mediated degradation of MHC class I HCs. More research will be required to identify the cellular proteins that link these processes.

## Materials & methods

### Cell lines

Wild-type FO-1 human melanoma cells <sup>33</sup>, which have a defect in  $\beta$ 2m gene expression and FO-1 cells restored for  $\beta$ 2m expression <sup>44</sup> were cultured in DMEM (Invitrogen, Breda, The Netherlands), supplemented with 10% FCS (Greiner BV, Alphen aan den Rijn, The Netherlands), 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin (Invitrogen, Breda, The Netherlands). HLA class I molecules expressed by FO-1 cells were genotyped as HLA-A\*2501, HLA-B\*0801 and HLA-Cw\*0701 <sup>44</sup>.

### Production of retrovirus and transduction

US2 and US11 cDNA fragments, subcloned into the pLZRS-IRES-EGFP vector were used for transfection of amphotropic Phoenix packaging cells to produce retrovirus, as described <sup>45-47</sup>. Cells were transduced with retrovirus using retronectin (Takara Shuzo, Otsu, Japan)-coated dishes. Transduced cells were sorted for EGFP expression using a FACS Vantage flow cytometer.

### Antibodies

The following antisera were used for immunoprecipitations: W6/32 (anti-MHC I complex; <sup>48</sup>), HC10 (anti-MHC I-free HCs; <sup>49</sup>), H68.4 (transferrin receptor; Zymed Laboratories, San Francisco, CA), US2 (anti-US2; <sup>46</sup>) and US11 (anti-US11; <sup>50</sup>).

### **Metabolic labeling, cell lysis, immunoprecipitation and SDS-PAGE**

Metabolic labeling, immunoprecipitations and SDS-PAGE were performed as described<sup>50</sup>. Where indicated, media were supplemented with the proteasome inhibitor carboxybenzyl-leucyl-leucyl-leucinal (ZL3H). For the experiments described in Fig. 1, 1 mM N-ethylmaleimide (NEM; Sigma-Aldrich, Zwijndrecht, The Netherlands) was added to the lysis mix to prevent post-lysis formation of disulfide bonds. Peptide-N-glycosidase F (PNGase F; Roche Diagnostics, Mannheim, Germany) was used according to the manufacturer's protocol. For experiments described in Fig. 2 and Fig. 3, immunoprecipitations were performed on denatured lysates. Cells were lysed in a smaller volume of Nonidet-P40 lysis mix (100  $\mu$ l/5  $\times$  10<sup>6</sup> cells) and after centrifugation, supernatants were transferred to a new tube with 1/10 volume of 10% SDS and 1/10 volume of 0.1 M DTT. Samples were boiled for 5 min to further denature proteins. Next, the volume was increased 10 times with non-denaturing buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.4, 300 mM EDTA, 0.02% NaN<sub>3</sub>) supplemented with protease inhibitors and 10 mM iodoacetic acid. Immunoprecipitates were taken up in sample buffer with (Fig. 2 and Fig. 3) or without  $\beta$ -mercaptoethanol (Fig. 1) and boiled for 5 min prior to loading onto 12.5 % SDS-PAGE acrylamide gels. Gels were screened with a Bio-Rad Personal Molecular Imager FX and analysed with Quantity One software.

### **Acknowledgements**

We would like to thank Dr. Patrizio Giacomini (Rome, Italy) and Dr. Soldano Ferrone (Buffalo, NY) for providing us with the FO-I wild-type and  $\beta$ 2m-reconstituted cell lines and Dr. Hidde Ploegh for providing reagents. This study was supported by the Council for Medical Research from the Netherlands Organisation for Scientific Research (Grant No. 901-02-218, MTB) and Grant RUL 1998-1791 from the Dutch Cancer Society (to GH).

### **REFERENCES**

- 1 Zinkernagel, R. and Doherty, P. (1974) Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. *Nature*. **251**, 547-548
- 2 Ljunggren, H. and Karre, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol.Today*. **11**, 237-244
- 3 Nossner, E. and Parham, P. (1995) Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules. *J.Exp.Med.* **181**, 327-337
- 4 Degen, E. and Williams, D. (1991) Participation of a novel 88-kD protein in the biogenesis of murine class I histocompatibility molecules. *J.Cell Biol.* **112**, 1099-1115

- 5 Galvin, K., Krishna, S., Ponchel, F., Frohlich, M., Cummings, D., Carlson, R., Wands, J., Isselbacher, K., Pillai, S. and Ozturk, M. (1992) The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene. *Proc.Natl.Acad.Sci.U.S.A.* **89**, 8452-8456
- 6 Leitzgen, K., Knittler, M. and Haas, I. (1997) Assembly of immunoglobulin light chains as a prerequisite for secretion. A model for oligomerization-dependent subunit folding. *J.Biol.Chem.* **272**, 3117-3123
- 7 Hammond, C., Braakman, I. and Helenius, A. (1994) Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. *Proc.Natl.Acad.Sci.U.S.A.* **91**, 913-917
- 8 Ellgaard, L. and Helenius, A. (2003) Quality control in the endoplasmic reticulum. *Nat.Rev.Mol.Cell Biol.* **4**, 181-191
- 9 Sugita, M. and Brenner, M. (1994) An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. *J.Exp.Med.* **180**, 2163-2171
- 10 Rajagopalan, S. and Brenner, M. (1994) Calnexin retains unassembled major histocompatibility complex class I free heavy chains in the endoplasmic reticulum. *J.Exp.Med.* **180**, 407-412
- 11 Walker, K. and Gilbert, H. (1997) Scanning and escape during protein-disulfide isomerase-assisted protein folding. *J.Biol.Chem.* **272**, 8845-8848
- 12 High, S., Lecomte, F., Russell, S., Abell, B. and Oliver, J. (2000) Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? *FEBS Lett.* **476**, 38-41
- 13 Sadasivan, B., Lehner, P., Ortmann, B., Spies, T. and Cresswell, P. (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. *Immunity.* **5**, 103-114
- 14 Solheim, J., Harris, M., Kindle, C. and Hansen, T. (1997) Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. *J.Immunol.* **158**, 2236-2241
- 15 Peterson, J., Ora, A., Van, P. and Helenius, A. (1995) Transient, lectin-like association of calreticulin with folding intermediates of cellular and viral glycoproteins. *Mol.Biol.Cell* **6**, 1173-1184
- 16 van Leeuwen, J. and Kears, K. (1996) Deglycosylation of N-linked glycans is an important step in the dissociation of calreticulin-class I-TAP complexes. *Proc.Natl.Acad.Sci.U.S.A.* **93**, 13997-14001
- 17 Serwold, T., Gonzalez, F., Kim, J., Jacob, R. and Shastri, N. (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. *Nature* **419**, 480-483
- 18 York, I., Chang, S., Saric, T., Keys, J., Favreau, J., Goldberg, A. and Rock, K. (2002) The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. *Nat.Immunol.* **3**, 1177-1184
- 19 Harris, M., Yu, Y., Kindle, C., Hansen, T. and Solheim, J. (1998) Calreticulin and calnexin interact with different protein and glycan determinants during the assembly of MHC class I. *J.Immunol.* **160**, 5404-5409
- 20 Hughes, E., Hammond, C. and Cresswell, P. (1997) Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. *Proc.Natl.Acad.Sci.U.S.A* **94**, 1896-1901
- 21 Park, B., Kim, Y., Shin, J., Lee, S., Cho, K., Fruh, K., Lee, S. and Ahn, K. (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. *Immunity.* **20**, 71-85

- 22 Ahn, K., Gruhler, A., Galocha, B., Jones, T., Wiertz, E., Ploegh, H., Peterson, P., Yang, Y. and Fruh, K. (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. *Immunity*. **6**, 613-621
- 23 Hengel, H., Koopmann, J., Flohr, T., Muranyi, W., Goulmy, E., Hammerling, G., Koszinowski, U. and Momburg, F. (1997) A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. *Immunity*. **6**, 623-632
- 24 Jones, T. and Sun, L. (1997) Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. *J.Virol.* **71**, 2970-2979
- 25 Wiertz, E., Jones, T., Sun, L., Bogyo, M., Geuze, H. and Ploegh, H. (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* **84**, 769-779
- 26 Wiertz, E., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T., Rapoport, T. and Ploegh, H. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature* **384**, 432-438
- 27 Furman, M., Loureiro, J., Ploegh, H. and Tortorella, D. (2003) Ubiquitinylation of the cytosolic domain of a type I membrane protein is not required to initiate its dislocation from the endoplasmic reticulum. *J.Biol.Chem.* **278**, 34804-34811
- 28 Ribaldo, R. and Margulies, D. (1992) Independent and synergistic effects of disulfide bond formation, beta 2-microglobulin, and peptides on class I MHC folding and assembly in an in vitro translation system. *J.Immunol.* **149**, 2935-2944
- 29 Wang, H., Capps, G., Robinson, B. and Zuniga, M. (1994) Ab initio association with beta 2-microglobulin during biosynthesis of the H-2Ld class I major histocompatibility complex heavy chain promotes proper disulfide bond formation and stable peptide binding. *J.Biol.Chem.* **269**, 22276-22281
- 30 Tector, M., Zhang, Q. and Salter, R. (1997) Beta 2-microglobulin and calnexin can independently promote folding and disulfide bond formation in class I histocompatibility proteins. *Mol.Immunol.* **34**, 401-408
- 31 Blom, D., Hirsch, C., Stern, P., Tortorella, D. and Ploegh, H. (2004) A glycosylated type I membrane protein becomes cytosolic when peptide: N-glycanase is compromised. *EMBO J.* **23**, 650-658
- 32 Gewurz, B., Gaudet, R., Tortorella, D., Wang, E., Ploegh, H. and Wiley, D. (2001) Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. *Proc.Natl.Acad.Sci.U.S.A* **98**, 6794-6799
- 33 D'Urso, C., Wang, Z., Cao, Y., Tataka, R., Zeff, R. and Ferrone, S. (1991) Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. *J.Clin.Invest.* **87**, 284-292
- 34 Tortorella, D., Story, C., Huppa, J., Wiertz, E., Jones, T., Bacik, I., Bennink, J., Yewdell, J. and Ploegh, H. (1998) Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential. *J.Cell Biol.* **142**, 365-376
- 35 Halaban, R., Cheng, E., Zhang, Y., Moellmann, G., Hanlon, D., Michalak, M., Setaluri, V. and Hebert, D. (1997) Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. *Proc.Natl.Acad.Sci.U.S.A* **94**, 6210-6215
- 36 Jackson, M., Cohen-Doyle, M., Peterson, P. and Williams, D. (1994) Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90). *Science*. **263**, 384-387

- 37 Hammond, C. and Helenius, A. (1995) Quality control in the secretory pathway. *Curr.Opin.Cell Biol.* **7**, 523-529
- 38 Plemper, R., Bohmler, S., Bordallo, J., Sommer, T. and Wolf, D. (1997) Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation. *Nature* **388**, 891-895
- 39 Chillaron, J. and Haas, I. (2000) Dissociation from BiP and retrotranslocation of unassembled immunoglobulin light chains are tightly coupled to proteasome activity. *Mol.Biol.Cell* **11**, 217-226
- 40 Ou, W., Cameron, P., Thomas, D. and Bergeron, J. (1993) Association of folding intermediates of glycoproteins with calnexin during protein maturation. *Nature*. **364**, 771-776
- 41 Oliver, J., van der Wal, F., Bulleid, N. and High, S. (1997) Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins. *Science* **275**, 86-88
- 42 Frenkel, Z., Shenkman, M., Kondratyev, M. and Lederkremer, G. (2004) Separate roles and different routing of calnexin and ERp57 in endoplasmic reticulum quality control revealed by interactions with asialoglycoprotein receptor chains. *Mol.Biol.Cell.* **15**, 2133-2142
- 43 Kamhi-Nesher, S., Shenkman, M., Tolchinsky, S., Fromm, S., Ehrlich, R. and Lederkremer, G. (2001) A novel quality control compartment derived from the endoplasmic reticulum. *Mol.Biol.Cell.* **12**, 1711-1723
- 44 Martayan, A., Fraioli, R., Giorda, E., Setini, A., Ciccarelli, G., Delfino, L., Ferrara, G. and Giacomini, P. (1999) Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. *Br.J.Cancer.* **80**, 639-649
- 45 Barel, M., Pizzato, N., van Leeuwen, D., Bouteiller, P., Wiertz, E. and Lenfant, F. (2003) Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. *Eur.J.Immunol.* **33**, 1707-1716
- 46 Barel, M., Ressing, M., Pizzato, N., van Leeuwen, D., Le Bouteiller, P., Lenfant, F. and Wiertz, E. (2003) Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. *J.Immunol.* **171**, 6757-6765
- 47 Dardalhon, V., Noraz, N., Pollok, K., Rebouissou, C., Boyer, M., Bakker, A., Spits, H. and Taylor, N. (1999) Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. *Hum.Gene Ther.* **10**, 5-14
- 48 Barnstable, C., Bodmer, W., Brown, G., Galfre, G., Milstein, C., Williams, A. and Ziegler, A. (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. *Cell.* **14**, 9-20
- 49 Stam, N., Vroom, T., Peters, P., Pastoors, E. and Ploegh, H. (1990) HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. *Int.Immunol.* **2**, 113-125
- 50 Kikkert, M., Hassink, G., Barel, M., Hirsch, C., van der Wal, F. and Wiertz, E. (2001) Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. *Biochem.J.* **358**, 369-377
- 51 Whitman, M., Strohmaier, J., O'Boyle, K., Tingem, J., Wilkinson, Y., Goldstein, J., Chen, T., Brorson, K., Brunswick, M. and Kozlowski, S. (2000) The isolated major histocompatibility complex class I alpha3 domain binds beta2m and CD8alphaalpha dimers. *Mol.Immunol.* **37**, 141-149

